If you want to know who actually controls Cosmo Pharmaceuticals NV (VTX: COPN), then you’ll need to look at the composition of its share register. Generally speaking, as a company grows, institutions increase their ownership. Conversely, insiders often decrease their ownership over time. We also tend to see a decline in insider participation in companies that were previously public.
With a market capitalization of 941 million francs, Cosmo Pharmaceuticals is a decent size, so it is probably on the radar of institutional investors. Looking at our ownership group data (below), it appears that institutions own shares in the company. Let’s dig deeper into each owner type to learn more about Cosmo Pharmaceuticals.
See our latest analysis for Cosmo Pharmaceuticals
What does institutional ownership tell us about Cosmo Pharmaceuticals?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it is included in a major index. We would expect most companies to have some institutions listed, especially if they are growing.
As you can see, institutional investors own a sizeable share of Cosmo Pharmaceuticals. This may indicate that the company has some degree of credibility in the investment community. However, it is best to be wary of relying on the so-called validation that accompanies institutional investors. They are also sometimes wrong. It is not uncommon to see a sharp decline in the stock price if two large institutional investors attempt to sell a stock at the same time. It is therefore worth checking the past earnings trajectory of Cosmo Pharmaceuticals (below). Of course, keep in mind that there are other factors to consider as well.
Cosmo Pharmaceuticals is not owned by hedge funds. Cassiopea SA is currently the main shareholder of the company with 33% of the outstanding shares. With respectively 7.5% and 4.7% of the outstanding shares, Heinrich Herz AG and dievini Hopp BioTech holding GmbH & Co. KG are the second and third largest shareholders.
Our research also shed light on the fact that approximately 53% of the company is controlled by the top 5 shareholders, suggesting that these owners wield significant influence over the company.
While it makes sense to study data on a company’s institutional ownership, it also makes sense to study analyst sentiment to find out which way the wind is blowing. There is some analyst coverage of the stock, but it could still become better known over time.
Insider ownership of Cosmo Pharmaceuticals
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The management of the company answers to the board of directors and the latter must represent the interests of the shareholders. In particular, sometimes the senior executives themselves sit on the board of directors.
I generally consider insider ownership to be a good thing. However, there are times when it is more difficult for other shareholders to hold the board accountable for decisions.
We note that our data does not show any board members personally owning shares. Not all jurisdictions have the same rules regarding insider ownership disclosure, and we may be missing something here. So you can click here to learn more about the CEO.
General public property
The general public, who are usually individual investors, hold a 38% stake in Cosmo Pharmaceuticals. While this size of ownership may not be enough to sway a policy decision in their favor, they can still have a collective impact on company policies.
Private Company Ownership
Our data indicates that private companies own 40% of the shares of society. It’s hard to draw conclusions from this fact alone, so it’s worth investigating who owns these private companies. Sometimes insiders or other related parties have an interest in shares of a public company through a separate private company.
I find it very interesting to see who exactly owns a company. But to really get insight, we also need to consider other information. Consider the risks, for example. Every business has them, and we’ve spotted 4 warning signs for Cosmo Pharmaceuticals you should know.
Ultimately the future is the most important. You can access this free analyst forecast report for the company.
NB: The figures in this article are calculated using trailing twelve month data, which refers to the 12 month period ending on the last day of the month in which the financial statements are dated. This may not be consistent with the annual report figures for the full year.
Feedback on this article? Concerned about content? Get in touch with us directly. You can also email the editorial team (at) Simplywallst.com.
This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.